Uncategorized-EN
7th SPAEN Conference 2016 Warsaw/Poland
Interest Group Developed Sarcoma Policy Checklist
On 8th of February 2017 a rare cancer policy debate at the European Parliament took place on how to improve the policy response to rare cancers, with a focus on sarcoma. Representatives from the ​European ​Commission, ​Member States, the ​European ​Parliament, ​industry ​delegates and ​sarcoma ​patients engaged in a policy debate on key challendes for…
Read MoreERNs start work March 1, 2017
Newly established European Reference Networks (ERNs) start their work March 1, 2017 24 thematic ERNs, gathering over 900 highly specialised healthcare units from 26 countries, will begin working together on a wide range of issues. Among them the ERN for Rare Solid Tumours EURACAN. SPAEN, along with other patient advocacy groups for rare…
Read MoreNew Desmoid Trial started in Belgium
eSurge 2016 Summary
On the 15th and 16th of November 2016, 50 surgeons from 13 different countries met in Institut Curie, Paris to attend the fifth edition of the esurge sarcoma surgery masterclass developed and directed by Dr Sylvie Bonvalot (Institut Curie) and Dr Alessandro Gronchi (Istituto di Tumori di Milano). Launched in 2010 as part of the…
Read MoreTazemetostat in Advanced Epithelioid Sarcoma
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Agents: Tazemtostat Phase III Status Recruiting Sponsor Epizyme, Inc Further information: https://www.clinicaltrials.gov/ct2/show/NCT04204941?term=tazemetostat&cond=sarcoma&phase=2&draw=2&rank=1 This is an international, double-blind and randomized phase 3 study to evaluate the efficacy and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in patients with advanced epithelioid…
Read MoreCrenolanib in patients with D842V mutated GIST
Randomized trial of Crenolanib in patients with D842V mutated GIST Trial name CrenoGIST Agents: Crenolanib vs. placebo Phase III Status Closed, active Sponsor Arog Pharmaceuticals, Inc. Further information: https://clinicaltrials.gov/ct2/show/NCT02847429?term=crenolanib+Gist&rank=2 WHO is the trial for? Patients with confirmed advanced or metastatic GIST with a D842V mutation in the PDGFRA gene Overall health status of the…
Read MoreShort Course Of Preoperative Radiotherapy in Extremity Soft Tissue Sarcomas (SCOPES)
Agents: Radiotherapy Phase II Status Recruiting Sponsor The Netherlands Cancer Institute Further information:Â https://www.clinicaltrials.gov/ct2/show/NCT04425967?term=Short+Course+Of+Preoperative+Radiotherapy+in+Extremity+Soft+Tissue+Sarcomas&cond=sarcoma&draw=2&rank=1 WHO is the trial for? Newly diagnosed intermediate to high grade soft tissue sarcoma localized to the extremities, trunk and chest wall or the head and neck area No regional and/or distant disease Overall health status of the patient has to be…
Read MoreCabozantinib in High Grade Uterine Sarcoma (HGUtS)
Maintenance therapy with Cabozantinib in High Grade Uterine Sarcoma (HGUtS) Agents: Cabozantinib Phase II Status Open, recruiting Sponsor EORTC Further information: https://clinicaltrials.gov/ct/show/NCT01979393 or http://www.eortc.org/research_field/clinical-detail/62113/ A phase II study evaluating the role of maintenance therapy with Cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to chemotherapy WHO is the trial for?…
Read MoreMilademetan versus trabectedin in dedifferentiated liposarcoma (MANTRA)
Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA) Agents: Milademetan vs. Trabectedin Phase III Status Recruiting Sponsor Rain Therapeutics Inc. Further information: https://www.clinicaltrials.gov/ct2/show/NCT04979442?term=mantra&cond=sarcoma&draw=2&rank=1 This is a Phase 3 registration study evaluating the safety and efficacy of milademetan compared to trabectedin in patients with unresectable or metastatic, progressing dedifferentiated liposarcoma. WHO is the…
Read More